S&P predicts modest growth for PPD; Oramed recruits Medpace for oral insulin trials;

> Looking at PPD, Standard & Poor's says the CRO's growth will be modest for the rest of the year, as escalating costs eat into profit. Story

> S. Eshwar Reddy, India's deputy drug controller, told in-PharmaTechnologist that India should not have to amend its good manufacturing practice laws to suit Western outsourcers. Article

> Laurantis Pharma has chosen Ark Therapeutics to manufacture and supply the lymphedema drug Lymfactin for Phase I trials. News

> Indian CRO Max Neeman International is expanding into Bangladesh, Sri Lanka and Malaysia to augment its operations in India, Europe and North America. More

> The FDA has called on investigators to include more children in clinical trials, but one expert says the industry is too wary of harming kids to follow through on the request. Item

> Oramed has signed on with CRO Medpace to conduct Phase II trials for ORMD-0801, the company's oral insulin capsule. Release

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.